A New Push Into Orphan Territory: Gorlin Syndrome
On April 17, 2026, Medicus submitted an Orphan Drug Designation application to the U.S. FDA for SkinJect® (D-MNA) for the treatment of basal cell carcinoma in patients with Gorlin Syndrome.
A few factors stand out about this move:
✔️ Gorlin Syndrome is a rare genetic disorder characterized by the development of multiple, recurrent skin cancers — patients can face hundreds of tumors over a lifetime
✔️ There are no approved drug therapies for the condition; current treatment relies on repeated surgical procedures associated with cumulative morbidity and disfigurement
✔️ The filing represents a strategic expansion of the SkinJect program into a high unmet need orphan indication
✔️ If granted, orphan drug designation typically provides development incentives including tax credits, fee waivers, and a period of marketing exclusivity upon approval
The Gorlin population is small, but it is also one of the most logical fits for a non-surgical, repeatable treatment approach.
Regulatory and Partnership Progress
Beyond the clinical data and the new ODD filing, Medicus has been building out its regulatory and commercial infrastructure.
Several developments are worth noting:
✔️ The FDA has supported the 505(b)(2) regulatory pathway for SkinJect, which could accelerate development timelines and reduce costs compared to a traditional new drug application
✔️ An end-of-Phase 2 meeting with the FDA is planned for the first half of 2026 to establish the Phase 3 pathway
✔️ The company has a strategic collaboration with the Gorlin Syndrome Alliance to pursue an expanded access program, giving patients with this rare genetic condition supervised access to SkinJect
✔️ An application has been submitted under the FDA Commissioner's National Priority Voucher Program, which could fast-track the review timeline
✔️ Clinical trials are being expanded internationally, with studies underway in the UK and UAE
A Second Pipeline Asset: Teverelix and Prostate Cancer
SkinJect is not Medicus Pharma's only development program. In August 2025, the company completed the acquisition of Antev Limited, a UK-based clinical-stage biotech developing Teverelix — a next-generation GnRH antagonist targeting advanced prostate cancer.
The rationale behind Teverelix centers on a significant gap in the existing treatment landscape:
✔️ Approximately 300,000 to 500,000 men in the U.S. are living with advanced prostate cancer
✔️ The standard treatment is androgen deprivation therapy (ADT), which lowers testosterone to slow disease progression
✔️ Existing GnRH agonists — a common class of ADT drugs — significantly increase cardiovascular risk
✔️ Cardiovascular disease accounts for roughly 30% of all non-cancer deaths in prostate cancer patients
✔️ Teverelix is designed to suppress testosterone rapidly without the initial testosterone surge that agonists cause, with a potentially more favorable cardiovascular safety profile
The FDA has granted clearance for a Phase 2B study on Teverelix, adding a second clinical catalyst to the company's near-term pipeline.
